NCT03507465

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 290 (estimated)
• Sponsor: Guangdong Provincial People's Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Patients with ER+/HER2- breast cancer (presumably the luminal A subtype) could potentially avoid the standard chemotherapy use. Letrozole Plus Low-Dose Metronomic Capecitabine may offer similar efficacy and less toxicity to standard chemotherapy in ER+/HER2- breast cancer patients.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Letrozole Plus Low-Dose Metronomic Capecitabine	Letrozole Plus Low-Dose Metronomic Capecitabine
DRUG	EC-T	Epirubicin/Cyclophosphamide Followed by Docetaxel

Timeline

• Start date: 2017-11-29
• Primary completion: 2019-11-29
• Completion: 2020-11-29
• First posted: 2018-04-25
• Last updated: 2018-04-25

Locations

1 site across 1 country: China